Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.
The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.
The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.
Shares of the company were down 2.2% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。